Other
Federal State Budgetary Institution of the Central Research Institute of Epidemiology of Rospotrebnadzor
Total Trials
2
Recruiting
0
Active
2
Completed
0
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
Failure Rate
0.0%
0 terminated/withdrawn out of 2 trials
Late-Stage Pipeline
50%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed trials have results
Key Signals
Enrollment Performance
Analytics
Phase 1
1(50.0%)
Phase 3
1(50.0%)
2Total
Phase 1(1)
Phase 3(1)
Activity Timeline
Global Presence
Loading network data...
Clinical Trials (2)
Showing 2 of 2 trials
NCT06320353Phase 3Active Not Recruiting
Study сomparing the Efficacy and Safety of RPH-075 and Keytruda® in Patients With Unresectable or Metastatic Skin Melanoma
Role: collaborator
NCT06307093Phase 1Active Not Recruiting
Study Comparing the Pharmacokinetics, Safety, and Efficacy of RPH-075 and Keytruda® in Patients With Malignant Neoplasms
Role: collaborator
All 2 trials loaded